U.K. agency favors NHS coverage of Remicade for colitis

12/17/2008 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence endorsed Schering-Plough's Remicade for National Health Service coverage as an alternative for patients with ulcerative colitis who do not respond to ciclosporin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY